It’s back-to-school season, which means parents are shuttling their kids to pediatricians for annual checkups — and advocates for and against states’ exemptions to vaccine mandates for school entry ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025.

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE ...

Cochlear’s Baha devices – as in bone-anchored hearing aid – cost around $10,000 locally. Strictly speaking, the $4 million ...

Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the ...

San Diego’s once-sizzling biotech scene is now in a cold snap. It’s left some workers desperate after months of fruitless job ...

Researchers have found that common viruses, like covid and the flu, can reactivate dormant breast cancer cells. In other news: Johnson & Johnson launches "The 3rd Opinion" initiative to empower ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

The rejection occurred amid broader turmoil at the FDA, which has been experiencing leadership changes, staff upheaval, and internal dysfunction. These organizational issues reportedly factored into ...

Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...

Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from ...

Exploring the impact and challenges of the 'Right to Try' legislation for experimental treatments.